Antibiotics

It is produced by the strain of Micromonospora megalomice var. megalomicea NRRL 3274. It is a macrolide antibiotic. It has anti-bacterial and mycobacterium activity, the activity is the strongest under alkaline condition, serum can reduce the activity of 20%-30%. It has protective effect on mice infected with Staphylococcus aureus, pneumococcus, E. coli and Pseudomonas aeruginosa.

It is produced by the strain of Pseudomonas aeruginosa T359. It's a phenazine antibiotic. It has antifungal and mycobacterium effects, and has weak inhibitory effect on gram-positive bacteria.

It is produced by the strain of Str. rimosus, Str. gilvus. It has anti-gram-positive bacteria, negative bacteria, mycobacterium effects. It also has inhibitory effect on mycoplasma, rickettsia, chlamydia, spirochetes and some protoplasm. It has been used clinically. It was cross-resistant to tetracycline and aureomycin, and partially resistant to chloramphenicol.

It is produced by the strain of Str. pactum var. pactum NRRL 2939. It is a cyclopentane and cyclohexane derivative antibiotic. It has anti-bacterial, virus, tumor activity.

It is produced by the strain of Pen. palitans. It is an antibiotic with antifungal and antiprotozoal properties.

It is produced by the strain of Actinomadura paroosalo. It's a glycopeptide antibiotic. It has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and enterococcus faecalis. Parvodicin C1 and C2 have stronger antibacterial effects than Parvodicin C3 and C4. The antibacterial activity of Parvodicin C is 1-4 times stronger than Tecomycin and 2-4 times stronger than vancomycin. The terminal branching activity of lipid chains is greater than straight chains (C1>C2>C3>C4, B1>B2), and the chain length is greater than short chains (C2>B). The half-life of Parvodicin C1 is longer in vivo than vancomycin and Archeomycin.

It is produced by the strain of Actinomadura paroosalo. It's a glycopeptide antibiotic. It has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and enterococcus faecalis. The terminal branching activity of lipid chains is greater than straight chains (C1>C2>C3>C4, B1>B2), and the chain length is greater than short chains (C2>B). It acts by inhibiting the synthesis of bacterial cell wall.

It is produced by the strain of Actinomadura paroosalo. It's a glycopeptide antibiotic. It has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and enterococcus faecalis. The terminal branching activity of lipid chains is greater than straight chains (C1>C2>C3>C4, B1>B2), and the chain length is greater than short chains (C2>B). It acts by inhibiting the synthesis of bacterial cell wall.

It is produced by the strain of Actinomadura paroosalo. It's a glycopeptide antibiotic. It has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and enterococcus faecalis. Parvodicin C1 and C2 have stronger antibacterial effects than Parvodicin C3 and C4. The antibacterial activity of Parvodicin C is 1-4 times stronger than Tecomycin and 2-4 times stronger than vancomycin. The terminal branching activity of lipid chains is greater than straight chains (C1>C2>C3>C4, B1>B2), and the chain length is greater than short chains (C2>B). The half-life of Parvodicin C1 is longer in vivo than vancomycin and Archeomycin.

It is produced by the strain of Pen. patulum. It has anti-bacterial and fungal effects.

It is produced by the strain of Pelagiobacter variabilis. It has strong activity against gram-positive bacteria and gram-negative bacteria, but no activity against candida albicans. It's cytotoxic to HeLa cells, BALB3T3 and BALB3T3/H-ras cultured in vivo with IC50 (μg/mL) of 0.04, 0.2 and 0.07, respectively. In vivo it has weak inhibitory effect on leukemia P388.

It is produced by the strain of Pen. puberulum. It is an antibiotic with activity against gram-positive bacteria, negative bacteria and mycobacterium. It is also used as a raw material for various semisynthetic penicillins. Penicillic acid, a kind of polyketide mycotoxin, has been found to restrain GDP-mannose dehydrogenase and sorts of other dehydrogenases. It causes DNA to break.

It is produced by the strain of Penicillium notatum NRRL 1209, Pen. chrysogenum NRRL 1951. It has strong activity of anti-gram-positive bacteria and spirochetes, and has weak anti-gram-negative bacteria activity. It is widely used in clinical practice.

It is produced by the strain of Str. violaceoniger AB 9991-80, Str. violaceoniger AB 1047T-33. It has effect against anaerobic bacteria. It is an antibiotic with good activity against gram-positive bacteria, notably clostridium difficile.

It is produced by the strain of Streptoverticillium verticillum 843-1. It's a heteropeptide antibiotic. It has anti-gram-positive bacteria, negative bacteria and mycobacterium effects. The therapeutic index of the complex for Solid Adenocarcinoma and Sarcoma-180 are 16. The therapeutic index of Ehrlician ascites cancer is 4-8. It acts an antibiotic originally, an anticancer agent and a selection agent for transformed algae, protista, animal and fungal cells.

It is produced by the strain of Streptoverticillium verticillum 843-1. It's a heteropeptide antibiotic. It has anti-gram-positive bacteria, negative bacteria and mycobacterium effects.

It is produced by the strain of Streptoverticillium verticillum 843-1. It's a heteropeptide antibiotic. It has anti-gram-positive bacteria, negative bacteria and mycobacterium effects. It extends the survival time of mice transplanted with Ehrman's ascites cancer by 300 percent with MED of 12.5-25 μg/mL. It inhibits airy entity carcinoma in mice with IC50 of 0.31 μg/mL.

It is produced by the strain of Str. flavovirens 65786. It has anti-mycobacteria, gram-positive bacteria and gram-negative bacteria effects, but the effect of anti-gram-negative bacteria is weak. It also has antitumor activity similar to colchicine.

Ribostamycin is an antibiotic produced by Streptomyces ribosidifcus. It is active against gram-positive bacteria.

SS-228Y is an antibiotic produced by Chainia Sp. It is active against gram-positive bacteria and Ehrlich's ascites carcinoma.